After receiving applications from a wide range of early stage and more established companies from across industries, the initial list was whittled down to 100 by D/SRUPTION. The list was then submitted to an expert judging panel. Judges from the likes of IBM, Shell, Digital Catapult and Remitly scored each applicant on their fulfilment of 10 criteria.
Exscientia has been named as 1 of the final 50 companies.
While the top 50 companies have now been announced, their final rankings remain under wraps until the 10th of September, where a presentation will be held at Disruption Summit Europe. During the Summit, guests will be able to meet the top 50 companies and understand how they are successfully disrupting business today. They’ll also be able to pick up a copy of the Disruption50 Index report – with full profiles of these innovative businesses. If that wasn’t enough, Unanimous AI will also be on hand to take us through the swarm intelligence process in depth.
Exscientia is at the forefront of Artificial Intelligence-driven drug discovery and design. As at 8th January 2019, Frontier IP Group Plc (LON:FIPP) have a 3.3% holding in Exscientia. Frontier IP Group, through its subsidiaries, engages in assisting universities, research institutions, and companies in the commercialization and exploitation of their intellectual property (IP) in the United Kingdom.